Volume 24 - Issue 11 - November 2016
Column
Voices
11/21/2016
David B. Spratte Jr. co-developed over-the-counter antiperspirant lotion to help sweaty palms and feet.
David B. Spratte Jr. co-developed over-the-counter antiperspirant lotion to help sweaty palms and feet.
David B. Spratte Jr....
11/21/2016
The Dermatologist
Spotlight
11/21/2016
Seth Orlow, MD, PhD, received his AB magna cum laude in biochemical sciences from Harvard.
Seth Orlow, MD, PhD, received his AB magna cum laude in biochemical sciences from Harvard.
Seth Orlow, MD, PhD, received...
11/21/2016
The Dermatologist
Chief Medical Editor Message
11/21/2016
I pity the dermatologist who doesn’t realize how good things are.
I pity the dermatologist who doesn’t realize how good things are.
I pity the dermatologist who...
11/21/2016
The Dermatologist
Department
Research in Review
11/21/2016
A study by Fleischer and colleagues, which recently was presented at the 2016 Fall Clinical Dermatology Conference, in Las Vegas, used data from the phase 3 clinical studies to evaluate whether econazole nitrate topical foam 1% also improved...
A study by Fleischer and colleagues, which recently was presented at the 2016 Fall Clinical Dermatology Conference, in Las Vegas, used data from the phase 3 clinical studies to evaluate whether econazole nitrate topical foam 1% also improved...
A study by Fleischer and...
11/21/2016
The Dermatologist
Board Review
11/21/2016
The contents of these questions are taken from the Galderma Pre-Board Webinar.
The contents of these questions are taken from the Galderma Pre-Board Webinar.
The contents of these questions...
11/21/2016
The Dermatologist
11/21/2016
The FDA recently awarded 21 new clinical trial research grants totaling more than $23 million over the next 4 years to boost the development of products for patients with rare diseases.
The FDA recently awarded 21 new clinical trial research grants totaling more than $23 million over the next 4 years to boost the development of products for patients with rare diseases.
The FDA recently awarded 21 new...
11/21/2016
The Dermatologist
11/21/2016
Topical diacerein 1% met its primary efficacy endpoint in a study of patients with epidermolysis bullosa simplex (EBS), according to final results from a phase 2 study presented at the 25th Annual Congress of the European Academy of...
Topical diacerein 1% met its primary efficacy endpoint in a study of patients with epidermolysis bullosa simplex (EBS), according to final results from a phase 2 study presented at the 25th Annual Congress of the European Academy of...
Topical diacerein 1% met its...
11/21/2016
The Dermatologist
